Tony Prentice is an innovative product developer, strategist, and leader with extensive experience building and running product, marketing, and partnership organizations. His career spans multiple industries including big data, healthcare, mobile applications, customer experience, financial services, and consumer products.
As Sema4’s Chief Product Officer, Tony is responsible for the strategy and execution of all product-related activities including our patient apps, provider apps, information products for health systems and pharma, clinical software, and new product development of our genomic solutions in Oncology and Women’s Health.
Prior to joining Sema4, Tony served as the Vice President of Mobile Payments at American Express, where he built the organization for new commerce products, applications, and mobile wallets. The team delivered enterprise strategy and products including Apple Pay, Android Pay, and the Amex app.
Previously, Tony held other senior product management roles at American Express for Gold Card, Starwood, Hilton and Blue cards. Before American Express, Tony had various product, general manager, and engineering roles at Starbucks, McKinsey & Company, and General Electric.
What is Anthony Prentice's net worth?
The estimated net worth of Anthony Prentice is at least $2,872.72 as of April 28th, 2022. Mr. Prentice owns 298 shares of GeneDx stock worth more than $2,873 as of April 20th. This net worth evaluation does not reflect any other investments that Mr. Prentice may own. Learn More about Anthony Prentice's net worth.
How do I contact Anthony Prentice?
Has Anthony Prentice been buying or selling shares of GeneDx?
Anthony Prentice has not been actively trading shares of GeneDx during the last quarter. Most recently, Anthony Prentice sold 51 shares of the business's stock in a transaction on Thursday, April 28th. The shares were sold at an average price of $71.94, for a transaction totalling $3,668.94. Following the completion of the sale, the insider now directly owns 298 shares of the company's stock, valued at $21,438.12. Learn More on Anthony Prentice's trading history.
Who are GeneDx's active insiders?
Are insiders buying or selling shares of GeneDx?
In the last year, GeneDx insiders bought shares 5 times. They purchased a total of 116,742 shares worth more than $491,562.34. In the last year, insiders at the sold shares 33 times. They sold a total of 78,447 shares worth more than $447,494.66. The most recent insider tranaction occured on March, 18th when CEO Katherine Stueland sold 8,559 shares worth more than $90,639.81. Insiders at GeneDx own 28.1% of the company.
Learn More about insider trades at GeneDx. Information on this page was last updated on 3/18/2024.
